Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1994-07-25
1997-06-24
Scheiner, Toni R.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
530324, A61K 3800, C07K 500, C07K 700, C07K 1700
Patent
active
056417470
ABSTRACT:
Bone resorption by osteoclast cells is promoted by activated vitamin D-binding factor, thereby providing an effective treatment for osteopetrosis. Conversely, inflammation-mediated bone loss is inhibited with antibody against the activated factor, providing a treatment for inflammation-mediated osteolytic diseases such as osteoporosis, osteoarthritis, rheumatoid arthritis and periodontal disease. The antibodies are further utilized in an antigen binding assay for diagnosing inflammation-mediated bone loss.
REFERENCES:
patent: 5177001 (1993-01-01), Yamamoto
patent: 5177002 (1993-01-01), Yamamoto
Key et al., The Journal of Pediatrics, vol. 121, pp. 119-124 (1992).
Wiktor-Jedrzejczale et al., Journal of Experimental Medicine, vol. 156, p516-1527 (1982).
Seifert, et al., Bone and Mineral, vol. 4, pp. 167-176 (1988).
Teitelbaum et al., Calcif. Tiss. Intl. vol. 27, pp. 255-261 (1979).
Murray et al., J. Bone Joint Surg (Br), vol. 72-B, pp. 988-992 (1990).
Popoff et al., J. Bone Min. Res. 8, Suppl. 1, S140 (Aug. 1993).
Schneider et al., FASEB J 8(4), A213 (Mar. 15, 1994).
Seifert et al., Clinical Orthopaedics 294, 23-33 (Sep. 1993).
Marks, Jr., Applied Pathology 5,: 172-183 (1987).
Marks, Jr., Clinical Orthopaedics 108, 239-263 (1984).
Chujo et al., Clin. Exp. Immunol. 76, 154-158 (1989).
Osawa et al., Biophysica et Biophysica Acta 1117, 271-278 (1992).
Mundy, J. Bone Min. Res. 8, Supp. 2: S505-510 (1993).
Yamamoto and Kumashiro, Infec. Immun. vol. 61, No. 12, 5388-5391 (1993).
Yamamoto et al., J. Immunol. vol. 151, 2794-2802, No. 5 (1993).
Homma et al., Immunology and Cell Biology 71, 249-257 (1993).
Yamamoto et al., Proc. Natl. Acad. Sci. USA 88, 8539-85432 (1991).
Yamamoto et al., J. Immunol, 147, 273-280 (1991).
Yamamoto et al., Immunology, 74, 420-424 (1991).
Baylink et al., J. Bone Min. Res. 8, Supp. 2: S565-572 (1993).
Yamamoto et al., J. Immunol. 152, 5100-5107 (May 15, 1994).
Marks, "Pathogensis of Osteopetrosis in the ia Rat: Reduced Bone Resorption Due to Reduced Osteoclast Function", Am. J. Anal. 138:165-190 (1973).
MacDonald, "Interferons" in Cytokines and Bond Metabolism, Maxine Gowen, Editor, CRC Press.
Marks et al., "Bone Cell Biology: The Reguluation of Development, Structure, and Function in the Skelton", Amer. J. Anal. 183:1-44 (1988).
Marks et al., "Osteoclast Biology in the Osteopetrotic (op) Rat", Amer. J. Anal. 186:325-334 (1989).
Popoff et al., "The Heterogeneity of the osteopetroses Reflects the Diversity of Cellular Influences During Skeletal Development", Bone 17(5):437-445 (1995).
Seifert et al., "Impaired Macrophage Migration in Incisors Absent (ia) Osteopetrotic Rats", Bone and Mineral 4:167-176 (1988).
Popoff et al., "Effect of Interferon-Gamma (IFN-.gamma.) on Skeletal and Immune Functions in Osteopetrotic Rats", J. Bone and Mineral Research, 1995 Program & Abstracts 10(1):s504 (T600).
Popoff et al., "Differential Gene Expression in Bone From Osteopetrotic and Normal Rats", J. Bone and Mineral Research, 1995 Program & Abstracts 10(1):S504 (T601).
Teitelbaum et al., "Malignant Osteopetrosis: a Disease of Abnormal Osteoclast Proliferation", Metabolic Bone Disease & Related Research 3:99-105 (1981).
Cournot et al., "Mineral Metabolism in Infants with Malignant Osteopetrosis: Heterogeneity in Plasma 1,25-Dihydroxyvitamin D Levels and Bone Histology", J. Bone and Mineral Research 7(1):1-10 (1992).
Popoff Steven N.
Schneider Gary B.
Finch University of Health Sciences/The Chicago Medical School
Huff Sheela J.
Scheiner Toni R.
Temple University-of the Commonwealth System of Higher Education
LandOfFree
Treatment of osteopetrotic diseases does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment of osteopetrotic diseases, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of osteopetrotic diseases will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-149127